Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Net Margin (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Net Margin for 2 consecutive years, with 229144.12% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 22909550.0% to 229144.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 199.44% through Dec 2025, up 30407.0% year-over-year, with the annual reading at 190.88% for FY2025, 29562.0% up from the prior year.
  • Net Margin hit 229144.12% in Q4 2025 for Silence Therapeutics, up from 13181.13% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 229144.12% in Q4 2025 to a low of 20091.55% in Q1 2025.